Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TK2 | O00142 | 5/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivudine SCHEMBL13030272 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4314668 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL141407 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL13674189 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL1172398 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4283382 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL99350 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL5983819 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL21316784 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL15405329 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140017336-A1 | CO-ADMINISTRATION OF ARSENIC COMPOUNDS AND ANTI-HERPES VIRUS ANTI-VIRALS | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-01-16 | — | — | US | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | TK1 732/4885CYP1A2 3115/4885CYP3A4 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.